Pharmacokinetics of lactosaminated recombinant human growth hormone in mice

被引:0
|
作者
Li, YC [1 ]
Guan, CT
Zhao, KQ
Chen, ZL
Li, TL
机构
[1] Sichuan Univ, W China Med Ctr, Affiliated Hosp 1, Dept Nucl Med, Chengdu 610041, Peoples R China
[2] Sichuan Normal Univ, Dept Chem, Chengdu 610066, Peoples R China
[3] Sichuan Univ, W China Med Ctr, Coll Pharm, Chengdu 610041, Peoples R China
[4] Sichuan Univ, W China Med Ctr, Affiliated Hosp 1, Dept Pharm, Chengdu 610041, Peoples R China
来源
ACTA PHARMACOLOGICA SINICA | 2001年 / 22卷 / 05期
关键词
somatotropin; pharmacokinetics; recombinant proteins;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
AIM: To study the pharmacokinetic characteristics of lactosaminated recombinant human growth hormone (hGH-L) in mice. METHODS: The biodistribution was studied with in vivo radioactive tracer technique. The pharmacokinetics was investigated by radioimmunoassy (RIA) method of hGH-L. The results were compared with that of recombinant human growth hormone (hGH). RESULTS: I-125-hGH-L has remarkable livertaxis. The area under drug concentration-time curve (32686.9 mug . min . L-1) in blood and serum mean residence time (21.4 min) of hGH-L are less than that of hGH (36913. 1 mug . min . L-1 and 24. 9 min) (P < 0.05). In target organ liver, hGH-L distribution half life (1.8 min) and elimination half life (11.1 min) are shorter than that of hGH (2.1 min and 27.7 min) (P < 0.05). The area under drug concentration-time curve (11621.9 mug . min L-1) of hGH-L is bigger than that of hGH (12148. 2 mug . min . L-1) (P < 0. 05) in liver. CONCLUSION: The pharmacokinetic paramters of hGH-L has obvious advantage over that of hGH.
引用
收藏
页码:450 / 454
页数:5
相关论文
共 50 条
  • [31] Use of Recombinant Human Growth Hormone in Children with Thalassemia
    Geffner, Mitchell E.
    Karlsson, Hanna
    HORMONE RESEARCH, 2009, 71 : 46 - 50
  • [32] Management of recombinant human growth hormone therapy at puberty
    Albers, N
    HORMONE RESEARCH, 1998, 49 : 58 - 61
  • [33] The Separation of Recombinant Human Growth Hormone Variants by UHPLC
    Karlsson, Goran
    Eriksson, Kathryn
    Persson, Annevi
    Mansson, Hakan
    Soderholm, Susanne
    JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2013, 51 (10) : 943 - 949
  • [34] Recombinant human growth hormone as potential therapy for osteoporosis
    Marcus, R
    BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1998, 12 (02): : 251 - 260
  • [35] Recombinant human growth hormone treatment of children on hemodialysis
    Etienne Bérard
    Hélène Crosnier
    Anne Six-Beneton
    Thierry Chevallier
    Pierre Cochat
    Michel Broyer
    Pediatric Nephrology, 1998, 12 : 304 - 310
  • [36] Recombinant human growth hormone and Gitelman's syndrome
    Ko, CW
    Koo, JH
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) : 778 - 781
  • [37] Pulmonary absorption of recombinant human growth hormone in rats
    Shao, ZJ
    Mitra, AK
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1996, 42 (03) : 199 - 203
  • [38] Safety of high doses of recombinant human growth hormone
    Van Loon, K
    HORMONE RESEARCH, 1998, 49 : 78 - 81
  • [39] Expanded spectrum of recombinant human growth hormone therapy
    Henwood, MJ
    Grimberg, A
    Moshang, T
    CURRENT OPINION IN PEDIATRICS, 2002, 14 (04) : 437 - 442
  • [40] Supercritical fluids processing of recombinant human growth hormone
    Velaga, SP
    Carlfors, J
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (02) : 135 - 149